Peripheral blood and bone marrow changes following 2'-deoxycoformycin therapy in hairy cell leukemia. Results of 200 weeks' follow-up.
Peripheral blood (PB) and bone marrow (BM) changes during 200 weeks' follow-up of 15 patients with hairy cell leukemia (HCL) undergoing low-dose 2'-deoxycoformycin (dCF) therapy are reported. Thirteen patients rapidly achieved complete remissions (CR) (median, 16 weeks). Previous splenectomy (two patients), or chemotherapy (two patients) had no effect on dCF response. Twelve patients have remained in CR. Patients with marked BM infiltration (hairy cell index [HCI] greater than 0.5; n = 5) had more pronounced pancytopenia and showed a slower hematologic recovery than those with a lesser degrees of infiltration. Additionally, patients with cytologic type II HCL (n = 5) had more pronounced pancytopenia with a greater tumor load in the BM, and exhibited slower hematologic recovery than those with type I (n = 5) HCL. There was a gradual decline in BM cellularity from 65% to 25% during year 1, a level which remained stable thereafter. Reticulin in the BM regressed in all nine patients in whom it was increased before dCF therapy. The authors have not seen any dysplastic changes in the hematopoietic cells during the period of follow-up.
Dalal
B I
BI
Department of Pathology, University of Manitoba, Winnipeg, Canada.
Freier
L
L
Johnston
J B
JB
Merry
C C
CC
Israels
L G
LG
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001853:Bone Marrow / Q000032:analysis / Q000187:drug effects* / Q000473:pathology; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015649:Pentostatin; D012074:Remission Induction; D012155:Reticulin / Q000032:analysis; D012263:Ribonucleosides / Q000627:therapeutic use*; D013163:Splenomegaly / Q000188:drug therapy
D000970:Antineoplastic Agents; D006454:Hemoglobins; D012155:Reticulin; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin